Standout Papers

Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre,... 2024 202648
  1. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial (2024)
    Yiming Mu, Freddy G. Eliaschewitz et al. The Lancet Diabetes & Endocrinology

Immediate Impact

3 from Science/Nature 67 standout
Sub-graph 1 of 21

Citing Papers

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
2025 Standout
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
1 intermediate paper

Works of Morten Hansen being referenced

Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
2024
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
2019

Author Peers

Author Last Decade Papers Cites
Morten Hansen 390 104 146 289 247 43 1.1k
Kristy Iglay 679 56 103 160 172 50 1.3k
Siew Pheng Chan 575 77 66 287 178 66 1.3k
Julien Bezin 220 166 178 145 142 67 1.1k
Jonathan Bouchard 869 114 98 183 166 51 1.4k
Amit D. Raval 319 85 151 164 121 77 1.2k
Stephanie H. Read 455 103 268 195 190 47 1.3k
Harvey Newnham 438 78 185 328 141 46 1.2k
Marietta Rottenkolber 285 86 127 220 366 65 1.4k
Kornelis J. J. van Hateren 445 66 281 258 437 49 1.2k
Carlo Piccinni 232 101 155 183 196 90 1.2k

All Works

Loading papers...

Rankless by CCL
2026